QVQ Holding BV
Webpage: QVQ Holding BV
QVQ Holding BV is a small biotech company that develops camelid-derived single domain antibody fragments (sdAb, VHH or nanobody) as a contract research supplier to universities, medical centres and the industry. QVQ has >15 years of experience in the field of generation, production, purification and conjugation of small camelid-derived antibody-fragments (VHH or nanobodies). In addition, QVQ develops an own pipeline of products for early detection, imaging and therapeutic treatment of cancer, infectious diseases and age-related diseases. QVQ has expertise in bioengineering VHH for the development of analytical and diagnostics tools and applies the llama-antibody technology for generating this pipeline of detection and imaging molecules.
Key research facilities, infrastructures and equipment
On-site facilities that QVQ offers include: phage-display technology (dedicated lab), expression and affinity purification (2x Äkta) of antibodies in bacteria and yeast (5L-fermentor), proprietary C-Direct tag that allows site-directional conjugation and bio-informatics to optimize affinity, production yields and purification. The location of QVQ on the Utrecht Science Park and collaborative partners provide access to many additional research facilities.
Dr. Ing. Raimond Heukers is CSO at QVQ Holding BV. As such, he is responsible for the technological expertise and progress of the company and for QVQs contribution to national and international research projects on the early detection and treatment of disease. Raimond has a background in chemistry, biochemistry and biomedical sciences. He obtained his PhD in cell biology at Utrecht University and then acquired additional expertise in the development and utilization of antibodies, fragments (like nanobodies), fusion constructs and other scaffolds for the manipulation and therapeutic targeting of tumor-related receptors. As a postdoc, dr. Heukers has established the nanobody selection platform at the VU for the discovery and characterization of GPCR-targeting nanobodies. He has (co-)authored 20+ peer reviewed publications and co-supervised multiple PhD students in various national and international projects, including ONCORNET1.0.
Dr. Edward Dolk is the (co-)founder and CEO of QVQ. He has 20+ years of experience with llama antibodies and an impressive network in scientific and business communities. Dr. Dolk contributed significantly to multiple scientific publications, a book chapter on selecting VHH under application conditions and 10+ patents.